Abuse-deterrent and tamper-resistant opioid formulations: What is their role in addressing prescription opioid abuse?

CNS Drugs

Volumn 24, Issue 10, 2010, Pages 805-810

  Schneider, Jennifer P ^a   Matthews, Michele ^b,c   Jamison, Robert N ^c  

^a Arizona Community Physicians   (United States)

^b MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Drug delivery systems; Opioid abuse; Opioid analgesics, abuse; Pain.

Indexed keywords

ACUROX; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; COL 003; ELI 216; EMBEDA; MORPHINE; NALTREXONE; NICOTINIC ACID; OPIATE; OXYCODONE; TQ 1017; TRAMADOL; UNCLASSIFIED DRUG;

ANALGESIA; CHRONIC PAIN; CLINICAL PRACTICE; DRUG ABUSE; DRUG DEPENDENCE; DRUG FORMULATION; HUMAN; NEUROPATHIC PAIN; PAIN; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK;

ANALGESICS, OPIOID; CHRONIC DISEASE; DELAYED-ACTION PREPARATIONS; DOSAGE FORMS; DRUG COMBINATIONS; DRUG COMPOUNDING; DRUG DESIGN; HUMANS; OPIOID-RELATED DISORDERS; PAIN; PRESCRIPTION DRUGS;

EID: 77956707359     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11584260-000000000-00000     Document Type: Review

References (43)

1. Ehrlich GE. Back pain. J Rheumatol Suppl 2003 Aug; 67: 26-31
2. Garofalo JB, Polatin P. Low back pain: an epidemic in in-dustrialized countries. In: Gatchel RJ, Turk DC, editors. Psychosocial factors in pain: clinical perspectives. New York: The Guilford Press, 1999: 164-174
3. Fordyce WE. Pain in the workplace: management of disability in non-specific conditions. Seattle (WA): IASP Press, 1995
4. Frymoyer JW, Cats-Baril WL. An overview of the in-cidences and costs of low back pain. Orthop Clin North Am 1991 Apr; 22 (2): 263-271
5. National Center for Health Statistics. Health, United States, 2006 with chartbook on trends in the health of Americans. Hyattsville (MD): U.S. Department of Health and Human Services, Office of Informational Services, 68-71
6. Maniadakis N, Gray A. The economic burden of back pain in the UK. Pain 2000 Jan; 84 (1): 95-103
7. Ferrari R, Russell AS. Regional musculoskeletal conditions: neck pain. Best Pract Res Clin Rheumatol 2003 Feb; 17 (1): 57-70
8. Stewart WF, Ricci JA, Chee E, et al. Lost productive time and cost due to common pain conditions in the US workforce. JAMA 2003 Nov 12; 290 (18): 2443-2454
9. Belouin S. Prescribing trends for opioids, benzodiazepines, amphetamines, and barbiturates from 1998-2007: US Public Health Service [online]. Available from URL: http:// nac.samhsa.gov/DTAB/ [Accessed 2010 Jul 8]
10. CDC. Unintentional drug poisoning in the United States [online]. Available from URL http://www.cdc.gov/ HomeandRecreationalSafety/pdf/poision- issue-brief.pdf [Accessed 2010 Apr 16]
11. Federation of State Medical Boards (FSMB). Model policy for the use of controlled substances for the treatment of pain. Dallas (TX): FSMB, 2004
12. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009; 10: 113-130
13. Roth SH, Fleischmann RM, Burch FX, et al. Around-the-clock, controlled-release oxycodone therapy for osteoar-thritis-related pain: placebo-controlled trial and long-term evaluation. Arch Intern Med 2000 Mar 27; 160 (6): 853-860
14. Nicholson B, Ross E, Sasaki J, et al. Randomized trial comparing polymer-coated extended-release morphine sulfate to controlled-release oxycodone HCl in moderate to severe nonmalignant pain. Curr Med Res Opin 2006 Aug; 22 (8): 1503-1514
15. Jamison RN, Raymond SA, Slawsby EA, et al. Opioid therapy for chronic noncancer back pain: a randomized prospective study. Spine 1998 Dec 1; 23 (23): 2591-2600
16. Katz N, Rauck R, Ahdieh H, et al. A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain. Curr Med Res Opin 2007 Jan; 23 (1): 117-128
17. Hale ME, Ahdieh H, Ma T, et al. Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study. J Pain 2007 Feb; 8 (2): 175-184
18. Webster LR, Butera PG, Moran LV, et al. Oxytrex mini-mizes physical dependence while providing effective analgesia: a randomized controlled trial in low back pain. J Pain 2006 Dec; 7 (12): 937-946
19. Gourlay D, HeitH. Universal precautions: a matter of mutual trust and responsibility. Pain Med 2006 Mar; 7 (2): 210-211
20. Savage SR, Kirsh KL, Passik SD. Challenges in using opi-oids to treat pain in persons with substance use disorders. Addict Sci Clin Pract 2008 Jun; 4 (2): 4-25
21. Mendelson J, Jones RT, Fernandez I, et al. Buprenorphine and naloxone interactions in opiate-dependent volunteers. Clin Pharmacol Ther 1996 Jul; 60 (1): 105-114
22. Fudala PJ, Yu E, Macfadden W, et al. Effects of buprenor-phine and naloxone in morphine-stabilized opioid addicts. Drug Alcohol Depend 1998 Mar 1; 50 (1): 1-8
23. Stoller KB, Bigelow GE, Walsh SL, et al. Effects of bupre-norphine/ naloxone in opioid-dependent humans. Psycho-pharmacology (Berl) 2001 Mar; 154 (3): 230-242
24. Strain EC, Preston KL, Liebson IA, et al. Acute effects of buprenorphine, hydromorphone and naloxone in metha-done-maintained volunteers. J Pharmacol Exp Ther 1992 Jun; 261 (3): 985-993
25. Harris DS, Jones RT, Welm S, et al. Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine. Drug Alcohol Depend 2000 Dec 22; 61 (1): 85-94
26. Simojoki K, Vorma H, Alho H. A retrospective evaluation of patients switched from buprenorphine (Subutex) to the buprenorphine/naloxone combination (Suboxone) [abstract]. Subst Abuse Treat Prev Policy 2008; 3: 16
27. Strain EC, Stoller K, Walsh SL, et al. Effects of buprenor-phine versus buprenorphine/naloxone tablets in non-dependent opioid abusers. Psychopharmacology (Berl) 2000 Mar; 148 (4): 374-383
28. Webster LR. PTI-821: sustained-release oxycodone using gel-cap technology. Expert Opin Investig Drugs 2007; 16 (3): 359-366
29. U.S. Department of Health and Human Services. FDA approves new formulation of OxyContin® [online]. Available from URL http://www.fda.gov/ NewsEvents/Newsroom/ PressAnnouncements/ucm207480.htm [Accessed 2010 Jul 8]
30. Fleming A, Noonan P, Wheeler A. Abuse-deterrent prop-erties and pharmacokinetics of a novel sustained release formulation of oxycodone for the treatment of moderate to severe pain [abstract]. J Pain 2008; 9 (4): 46. Plus poster presented at the 27th Annual Scientific Meeting of the American Pain Society; 2008 May 8-10; Tampa (FL)
31. Katz N, Sun S, Fox L, et al. Efficacy and safety evaluation of an extended-release morphine sulfate formulation with sequestered naltrexone for the treatment of osteoarthritis [abstract]. J Pain 2008; 9 (4): 41. Plus poster presented at the 27th Annual Scientific Meeting of the American Pain Society; 2008 May 8-10; Tampa (FL)
32. Johnson F, Stark JC, Bieberdorf FA, et al. Relative bioavailability of naltrexone from crushed ALO-01, an investigational extended-release, abuse-deterrent morphine sulfate formulation with sequestered naltrexone, compared with naltrexone solution [abstract]. Clin Pharmacol Ther 2008 Apr 3; 83 Suppl. 1: S28
33. Brinker A, Bonnel RA, Beitz J. Abuse, dependence, or withdrawal associated with tramadol. Am J Psychiatry 2002; 159: 881-882
34. Cicero TJ, Adams EH, Geller A, et al. A postmarketing surveillance program to monitor Ultram (tramadol hy-drochloride) abuse in the United States. Drug Alcohol Depend 1999; 57: 7-22
35. Senay EC, Adams EH, Geller A, et al. Physical dependence on Ultram (tramadol hydrochloride): both opioid-like and atypical withdrawal symptoms occur. Drug Alcohol Depend 2003; 69: 233-241
36. Knisely JS, Campbell ED, Dawson KS, et al. Tramadol post-marketing surveillance in health care professionals. Drug Alcohol Depend 2002; 68: 15-22
37. Mehlisch D, Babul N, Baum D, et al. Novel abuse-deterrent extended-release SECUREL dosage forms of tramadol. 12th World Congress on Pain; 2008 Aug 17-22; Glasgow
38. Lavine G.Abuse deterrence focusofupcoming opioid formul-ations. Am J Health Syst Pharm 2008 Mar 1; 65 (5): 381-385
39. Jasinski DR. Evaluation for flushing, safety, and tolerability of niacin in combination with 40 mg oxycodone combination with 40 mg oxycodone [abstract]. Clin Pharmacol Ther 2008 Apr 3; 83 Suppl. 1: S20
40. Coalition Against Insurance Fraud. Prescription for peril: how insurance fraud finances theft and abuse of addictive prescription drugs [online]. Washington, DC: Coalition Against Insurance Fraud 2007. Available from URL http://www.insurance fraud.org/drugDiversion.htm [Accessed 2008 Aug 25]
41. White AG, Bimbaum HG, Roth DB, et al. Development of a budget-impact modeltoquantify potential cost savings from prescription opioids designed to deter abuse or ease of extraction. Appl Health Econ Health Policy 2009; 7 (1): 61-70
42. Bruce RD, Govindasamy S, Sylla L, et al. Lack of reduc-tion in buprenorphine injection after introduction of co-formulated buprenorphine/ naloxone to the Malaysian market. Am J Drug Alcohol Abuse 2009; 35 (2): 68-72
43. Choose Help.com. Getting high onSuboxone? The FDA says it's happening: ex-NIDA director blames doctors [online]. Available from URL http://www.choosehelp.com/news/ getting-high-on-suboxone-the-fda-says-its- happening-ex-ni da-director-blames-doctors.html [Accessed 2010 Apr 23]